Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Global Pharma 4.0 Market Projected to Grow at a CAGR of 15-20 Percent from 2019-2025

By IndustryARC | May 22, 2019

Pharma 4.0, an operating model for pharmaceutical factories and supply chains is based on Industry 4.0 capabilities, digital maturity, and data integrity by design. It focuses on technology, integration, work force and quality control. It is fueled by developments in big data, interconnectivity, collaborative robotics, artificial intelligence and distributed cloud service-based architectures. Digitalization is enabling the change across the organization and along the value chain network. With Pharma 4.0, virtual value chain relies on seamless, real-time data exchange and not on paper filing. Continuous, real-time monitoring of manufacturing processes is possible through Pharma 4.0 thus eradicating any drift away from specified parameters. It enables prediction and rectification before anything turns into a deviation, avoiding the associated down time and loss of product.

Pharma 4.0 is aimed at reducing pharmaceutical manufacturing problems by increasing quality and productivity coupled with decreasing risk and waste. Companies such as Johnson & Johnson, Vertex, Glatt, GSK, Lonza and Pfizer has been seamlessly working on implementation of Pharma 4.0 and has been successful in gaining approvals form regulatory bodies and reap benefits. Considering Pharma 4.0 of strategic value and creating a corporate culture to nurture its growth is of prime importance for companies to succeed with Pharma 4.0 implementation. The cost of fitting out a pharmaceutical manufacturing site according to Pharma 4.0 principles is high, however the results may quickly offset the cost by increasing the productivity and reduction of down time and waste. Recently, ViforPharma Group and its partner company Goodly Innovations were awarded the 2018 Pharma 4.0 Award for the innovation of the year in manufacturing execution systems in the pharma industry. ViforPharma was the first company to pilot a dynamic team-based augmented reality system in a pilot project at its site. Drug development is another area where Pharma 4.0 can be implemented. Most of the data in this area is in unstructured form and thus Pharma 4.0 can enable speeding up and the connection of unstructured data.

Predictive Analysis plays key role in Pharma 4.0 owing to the monitoring capabilities today throughout the production cycle. However the amount of stored data which is in unstructured, dispersed, incomplete form acts as a barrier. Difficulty in predicting what skills industry will require in coming years to run the analytics, is another key factor impacting the Pharma 4.0 adoption. As Pharma 4.0 involves connecting thousands of individual devices such as sensors, actuators and networks, security acts as another concern. Thus investments in skilled security staff will lead to reap the benefits of Pharma 4.0 and mitigate the security risks for the companies.

Pharma 4.0 has given manufacturing intelligence a new meaning and is set to facilitate generational change in manufacturing. It is providing the ability to move from reactive to predictive and from strict to adaptive process control. This is creating “smart” manufacturing and is adding flexibility to physical processes involved. With the continuous and cautious testing, Pharma 4.0 concept is gaining momentum. FDA has been actively encouraging the pharma industry to catch up with other industries with regards to the adoption of the Industry 4.0. Along with the big pharmaceutical companies, small and medium companies can also reap the benefits of Pharma 4.0 and thereby become advance manufacturers. As data integrity expectations for regulators increase, demand for more flexible manufacturing, personalized medicine, smaller batch sizes and continuous manufacturing grows, pharmaceutical companies needs to focus on climbing the steep part of the adoption curve in order to make digital manufacturing plant a reality.

Related Articles Read More >

Novartis logo
Novartis mulls sale of $25 billion Sandoz generics arm
Pfizer logo
Pfizer seeks to comply with voluntary Net-Zero Standard by 2040
Fujifilm Diosynth Technologies
Fujifilm to spend $1.6B to bolster cell culture manufacturing services
Zantac
First Zantac trial slated for February 2023

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards